Maintenance therapy for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with advanced (stage III or IV) ovarian, fallopian tube, or primary peritoneal cancer that is high-grade.
- You have completed 6 to 8 cycles of first-line platinum-based chemotherapy.
- You received bevacizumab (a drug that blocks blood vessels) with your last three chemotherapy cycles.
- You have a tissue sample (tumor) available for testing, or you have had surgery to remove the tumor or your cancer cannot be operated on.
- Your cancer has not grown after initial treatment, and your tumor is 'HRD negative' (a genetic marker).
- You have not had certain lung problems, non-healing wounds, active ulcers, bowel blockage, or prior treatment with certain targeted therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called torvutatug samrotecan, alone or with bevacizumab, as a maintenance therapy after chemotherapy for ovarian cancer that has come back. It aims to help keep the cancer from growing for a longer time.
This study tests a new maintenance therapy for people with advanced ovarian cancer that has responded well to initial chemotherapy. The goal is to see if it helps keep the cancer from coming back.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
This study tests whether adding a targeted therapy (trastuzumab) to the usual maintenance drug (bevacizumab) helps keep ovarian cancer from coming back after first-line chemo. It is for people with certain genetic markers and who have completed initial treatment without the cancer growing.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.